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While modern treatments have led to a dramatic improvement in survival for pediatric malignancy, toxicities are high and a sig-
niﬁcant proportion of patients remain resistant. Gene transfer oﬀers the prospect of highly speciﬁc therapies for childhood cancer.
“Corrective” genes may be transferred to overcome the genetic abnormalities present in the precancerous cell. Alternatively, genes
can be introduced to render the malignant cell sensitive to therapeutic drugs. The tumor can also be attacked by decreasing its
blood supply with genes that inhibit vascular growth. Another possible approach is to modify normal tissues with genes that make
them more resistant to conventional drugs and/or radiation, thereby increasing the therapeutic index. Finally, it may be possible
to attack the tumor indirectly by using genes that modify the behavior of the immune system, either by making the tumor more
immunogenic, or by rendering host eﬀector cells more eﬃcient. Several gene therapy applications have already been reported for
pediatric cancer patients in preliminary Phase 1 studies. Although no major clinical success has yet been achieved, improvements in
gene delivery technologies and a better understanding of mechanisms of tumor progression and immune escape have opened new
perspectives for the cure of pediatric cancer by combining gene therapy with standard therapeutic available treatments.
INTRODUCTION
Amultidisciplinaryapproachcombiningsurgery,che-
motherapy, and bone marrow transplantation has led to
a dramatic improvement in survival for pediatric malig-
nancy over the past 20 years. Currently, overall 5-year sur-
vival rates are more than 75% for children younger than
15 years of age and 77% for 15–19 year olds [1]. But de-
spite these advances in the treatment of pediatric cancer, a
signiﬁcant proportion of patients remain resistant to the
standard therapeutic procedures. Moreover, the price of
the cure is often unacceptable, and includes not just acute
and chronic organ toxicity but most troublingly, an in-
creased risk of secondary malignancy. Hence, new strate-
g i e sa r er e q u i r e dt oi m p r o v et h eo v e r a l ls u r v i v a lr a t ea n d
decrease treatment-related morbidity.
Gene therapy oﬀers the prospect of eﬃcient and
highly speciﬁc therapy for childhood cancer, and the con-
cept was initially welcomed by investigators and clinicians
alike with great enthusiasm mixed with unrealistic ex-
pectations. Unfortunately, it has become evident that the
complexities of childhood malignancy and the limitations
of current gene transfer vectors mean that the success-
ful application of gene transfer technologies for the cure
of pediatric malignancy will be a gradual and progressive
process over many years. Nonetheless, as we will describe
here, gene transfer technologies are already successfully
being applied to the treatment of childhood cancer and
should increasingly beneﬁt this patient group in the com-
ing years.
Genes may be transferred to cells in vitro with subse-
quent transfer of the gene-modiﬁed cells to the patient,
or transfer may take place directly to the target cells in
vivo. The gene delivery system, or vector, generally con-
sists of a speciﬁc DNA sequence and promoter that drives
the expression of the transgene of interest, as well as a
polyadenylation signal that stabilizes the speciﬁc messen-
ger RNA. The vector usually takes the form of a modi-
ﬁed virus, but synthetic nonviral vectors are playing an
increasingly important role [2, 3, 4].
There are a number of ways in which these transferred
genes may be used for the treatment of cancer. The most
obvious, and perhaps the most intellectually appealing,
is to transfer corrective genes that will help overcome the
genetic abnormalities that have arisen in the precancer-
ous cell and led to the malignant process. Alternatively, it
is possible to introduce genes that will render the malig-
nant cell sensitive to small molecules to which it might
otherwise be resistant. The third approach is to attack
the tumor blood supply with genes that inhibit vascular
growth or function. The fourth is to leave the tumor un-
modiﬁed but to alter normal tissues instead, so that they14 Ettore Biagi et al 2003:1 (2003)
Table 1. Advantages and disadvantages of vector systems.
Vector Advantages Disadvantages Current uses
Murine retrovirus
Stable integration into dividing Low titer Marker studies
cells Only integrates in dividing cells Gene therapy approaches using
Minimal immunogenicity Limited insert size hemopoietic stem cells
Stable packaging system Risk of silencing or T cells, for example, to treat
Risk of insertional mutagenesis immunodeﬁciency syndromes
Transduction tumor cell lines
Lentivirus
Integrates into dividing cells No stable packaging system No approved trials as yet
Integrates into nondividing cells Complex safety issues
Larger insert size than murine
retroviruses
Self-inactivating lentiviral
vectors (SIN-Lenti)
Incapable of replication post Safety concerns remain No approved trials as yet
transfection → ? increased safety
Stable packaging system
Adenovirus
Infects wide range cell types Highly immunogenic Direct in vivo applications
Infects nondividing cells Nonintegrating Transduction tumor cells
High titers
High level of expression
Accepts 12–15kb DNA inserts
Adeno-associated virus
(AAV)
Integrates into dividing cells No stable packaging cell line Gene therapy approaches using
Infects wide-range cell types Very limited insert size hemopoietic stem cells
Herpesvirus
High titers No packaging cell lines Transduction tumor cells
Transduces some target cells Nonintegrating Neurologic disorders
at high eﬃciency May be cytotoxic to target cell
Accepts large DNA inserts
Liposomes and other
physical methods using
plasmid DNA
Easy to prepare in quantity Ineﬃcient entry into target cell Topical applications
Virtually unlimited size Nonintegrating Transduction tumor cells
Limited immunogenicity
are more resistant to conventional drugs and/or radiation
and thereby increase the therapeutic index. Finally, and
perhaps most widely used of all, it may be possible to at-
tack the tumor indirectly by using genes to modify the be-
havior of the immune system, either by making the tumor
more immunogenic, or by rendering host eﬀector cells
more eﬃcient.
While each of these approaches has its advantages and
disadvantages, at the moment all must be tempered by an
appreciation that none of the current vectors with which
we work possess the desirable characteristics of high eﬃ-
ciency and speciﬁc targeting to the tumor and tumor cell
DNA.Formanygenetherapyapproaches,itwouldalsobe
highly desirable to control the transgene product, some-
thing that is not yet readily achievable in humans, and it
would also be helpful to further improve the safety of vi-
ral vectors. While each of the available vectors has advan-
tages and disadvantages, at present none comes close to
meetingtherequirementsforatrulyeﬀectivegenetherapy
vector that could be used in all the approaches outlined
above. Instead, the choice of a vector system is based on
the “least bad” alternative for the proposed use. An out-
line of the advantages and disadvantages of each of the
vector systems is given in Table 1, while a more detailed
account of each of these vectors can be obtained from ref-
erences [2, 5, 6, 7, 8].
TUMOR CORRECTION
Tumors are increasingly being characterized by their
molecularaberrations.Manyofthesedefectsinvolvedele-
tions in molecules important in regulating cell growth,
survival, or diﬀerentiation, while others lead to the for-
mationofmutantfusionproductsprovidinganunwanted
gain of function aﬀecting the same critical activities.
Gene therapy could in principle be used to replace an
inactive gene with an active one, or to neutralize the be-
havior of a gain of function mutation. In adults, such ef-
forts have been made, apparently with some success, in
the treatment of p53 deﬁcient head and neck tumors and
carcinoma of the bronchus [9, 10, 11]. No equivalent pe-
diatric trials have been reported, and formidable prob-
lems remain before this approach can be fully exploited.
For example, it will be necessary to get a corrective gene
into an extremely high proportion of malignant cells, al-
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uncharacterized bystander eﬀect on nontransduced tu-
mor. Secondly, targeting to metastatic tumor will usually
be necessary. Thirdly, correction of a single defect may be
inadequate to actually kill the tumor cells, leaving instead
acollectionof“n−1cells”(wherenisthenumberofmuta-
tions required for malignancy to occur) capable of under-
going another mutation to restart the malignant process.
Finally, since many of the mutations observed are gain of
function and/or have a dominant phenotype, introduc-
tion of a wild-type gene alone is insuﬃcient. Instead, the
mutant gene or its products must be neutralized using
strategies that include introduction of ribozymes or an-
tisense RNA or of siRNA that are proving troublesome to
develop [12, 13].
Hence, exploitation of the tumor correction approach
will require signiﬁcant improvements in vector eﬃciency
and targeting, and until these come to pass, the devel-
opment of novel rationally targeted small molecules will
likely dominate this approach.
PRODRUG-METABOLIZING ENZYME (PDME)
Introduction of a gene encoding an enzyme which
metabolizes an otherwise inert molecule into a cytotoxic
agent has frequently been used in tumor gene therapy. Al-
though the herpes simplex thymidine kinase-ganciclovir
system has been most widely applied, there are in fact
more than 20 such PDME systems currently in various
stages of development and/or clinical trials [14, 15]. For
all of these, the concept is that the gene encoding the
prodrug-metabolizing enzyme is expressed in the cancer
cell, and metabolizes a small molecule to an active moi-
ety which then kills the tumor cell directly. The molecule
may also diﬀuse either through intercellular gap junctions
or in the extracellular space and destroy adjacent tumor
cells. In this way, transduction of even a small proportion
of tumor cells can produce a large bystander eﬀect on ad-
jacent tumor tissue. This in turn compensates for the low
eﬃciency of transduction achieved by currently available
vectors and may help to destroy a large tumor burden.
PediatricclinicalstudiesofgenetictransferofPDME
Brain tumors were an attractive initial target for
PDME gene therapy. Since the tumors seldom metasta-
size, the goal of the therapy is the local eradication of the
tumor. Hence, the major limitation of PDME, that it re-
quires local inoculation of a tumor with the vector encod-
ing the gene, does not represent a major disadvantage. A
numberofadultstudieshavebeenperformedusingretro-
viral and, more recently, adenoviral vectors [16, 17, 18],
but to date only one pediatric study has been reported in
patientswithrecurrentorprogressivesupratentorialbrain
tumors [19]. Twelve children were enrolled and after tu-
mor resection they weretreated with instillation in the tu-
mor bed of retroviral producer cells generating particles
encoding HSV-tk followed by ganciclovir administration.
Unfortunately, disease progression was seen in 10 of 11
patients, although one patient remained free of progres-
sion for 18 months.
More recently, a study has been performed on pa-
tients with retinoblastoma [20, 21], which is also a highly
localized tumor that is conventionally, treated by enu-
cleation and/or chemoradiotherapy. Enucleation is obvi-
ously disabling and deforming, and if the tumor is bilat-
eral it leads to blindness. The alternatives of chemother-
apy and radiotherapy are less mutilating but both are as-
sociatedwithsecondarymalignancies.InastudyatBaylor
College of Medicine, Hurwitz and colleagues are injecting
bilateral retinoblastomas with adenovirus type 5 encod-
ingthethymidinekinasegene,followedbyadministration
of ganciclovir. Two of the ﬁrst three patients have shown
substantial tumor responses with the Ad-tk and both are
disease free, with retained vision, at up-to-one-year post
therapy. This trial is now accruing patients with monolat-
eral retinoblastoma.
FuturetrendsinPDMEtherapy
Other suicide gene therapies are being evaluated.
Amongst the most developed of these is the cytosine
deaminase system, which converts ﬂuorocytosine to ﬂu-
orourosil [22]. There are, however, concerns that this sui-
cidesystemmaybelesspotentthanthetk-ganciclovirpro-
drug system. Other molecules which metabolize drugs or
trigger apoptotic pathways within tumor cells are also be-
ing considered. Perhaps the most important future trend
is to attempt to enhance the bystander eﬀect. At present,
this is mediated predominantly by transfer of the small
molecule cytotoxic drug from cell to cell. However, it is
apparent that at least part of the bystander eﬀect is depen-
dent on an immune response generated to the lysed tu-
mor.Hence,thebystandereﬀectinimmunocompromised
animals has been observed to be substantially less than in
those with intact immune systems. Investigators are now
attempting to combine PDME genes with sequences en-
coding a variety of immunostimulatory molecules (see
section “Gene Modiﬁcation of The Immune Response”),
including but not limited to Interleukin 2, Interleukin 12,
and GM-CSF [23, 24, 25, 26, 27, 28]. Data from these
studies are yet to be evaluated. Eﬀorts are also being made
to generate vectors, which can selectively divide in malig-
nant cells (conditionally replication-competent vectors)
and may therefore spread their encoded PDME genes
throughout the tumor bed [29].
PDME has also eﬀectively been used as a means of
controlling T cell therapies. For example, graft versus host
diseasemayoccurwhendonorTcellsaregiventopatients
after allogeneic stem cell transplantation in an eﬀort to
t r e a tt u m o rr e l a p s e( g r a f tv e r s u st u m o re ﬀect) or post-
transplant infections. Several groups have infused donor
TcellstransducedwiththeHSV-tkgeneandreportedsuc-
cessful abrogation of GvHD after treatment with ganci-
clovir [30, 31]. More recently eﬀorts have been made to
induceexpressionofthedeathsignal,Fas,indonorTcells.
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occursonlyinthepresenceofanorallyadministeredsmall
molecule (rapamycin or its analogues) that dimerises two
individually inactive components of a Fas transcriptional
regulator,leadingtoexpressionoftheFasreceptorandcell
death on exposure to the ligand [32].
As T cell therapies for cancer become more wide-
spread, these suicide mechanisms will become extremely
important in ensuring that the regimens are acceptably
safe.
ANTIANGIOGENESIS GENE THERAPY
Because angiogenesis is a prerequisite for the develop-
ment of metastatic disease for solid tumors, and probably
for leukemias and lymphomas as well, an attack on newly
formed blood vessels may help impede the spread of the
disease. A number of diﬀerent large and small molecule
inhibitors are currently under study and some of these
are suitable for a gene therapy approach [33]. For ex-
ample, endostatin, a 20-kilodalton fragment of collagen
XV111 can eﬃciently block angiogenesis, but the recom-
binant protein is diﬃcult and expensive to produce and
is somewhat unstable. Delivery of endostatin in murine
tumor models by several diﬀerent vector systems has been
able to overcome this limitation and has proved extremely
promising [34, 35, 36]. Similarly, angiostatin, a fragment
of plasminogen, also functions as a large molecule in-
hibitor of vessel growth and impedes metastastic tumors.
This too can be transferred (eg, by adeno-associated virus
vector) to produce beneﬁt in animal models of malignant
brain tumors [37, 38].
Much remains to be learned about the most appropri-
ate route and cell of delivery of angiogenesis inhibition,
but as with any protein-based therapeutic, gene transfer
should allow a continual delivery of the drug rather than
the peak and trough concentrations that result from most
forms of injection, and may thereby produce a more sus-
tained and eﬀective response.
CYTOTOXICDRUG RESISTANCE GENE TRANSFER
The concept of dose intensiﬁcation has long been cur-
rentinmodernoncology,includingpediatriconcology.In
other words, it is believed that giving more of a cytotoxic
drug over a longer period will cure a higher proportion of
patients. While there are many obvious exceptions to this
rule, for many pediatric malignancies it is clear that fail-
ure to tolerate chemotherapy in the intended doses corre-
lates well with an increased risk of relapse. For that rea-
son, there is an interest in using genes which will protect
normal tissues while leaving malignant cells vulnerable to
destruction. By increasing the therapeutic index in this
way, it is hoped that more drug can be administered and a
higher percentage of patients cured.
There are many diﬀerent candidate drug resistance
genes to be transferred, but perhaps the most widely
studied is the human Multidrug Resistance-1 (MDR-1)
gene. The gene product acts as a drug eﬄux pump
and prevents accumulation of toxic small molecules,
including a range of cytotoxic drugs such as mitox-
antrone and daunorubicin. The primary toxicity of many
of these cytotoxic drugs is on hematopoietic progeni-
tor cells. Retroviral-mediated gene transfer of drug resis-
tance genes into hematopoietic stem cells has, until re-
cently, been diﬃcult to accomplish. The incorporation
of ﬁbronectin together with hematopoietic growth fac-
tors into the transduction regimen, together with re-
peated cycles of gene transfer, has allowed a signiﬁcant
proportion of hematopoietic cells to be protected with
expression levels adequate to reduce the sensitivity of
these stem cells to chemotherapeutic agents [39]. Sev-
eral other drug resistance genes are currently under study
and may soon join MDR-1 in clinical trial. These include
the bacterial nitroreductase gene (which protects against
drugs such as thiotepa) [40] and dihydrofolate reductase
mutants which protect against methotrexate/trimetrexate
[41].
There are two major problems with using transfer of
drugresistancegenes.Thelackoftargetingofcurrentvec-
torsmeansthattheymaytransducemalignantcellsaswell
as normal cells, and therefore increase the resistance of
bothtothecytotoxicdrug.Moreover,whileitmaybepos-
sible to protect a signiﬁcant proportion of marrow stem
cells, secondary toxicities to other organ systems such as
skin, lung, and gut will rapidly become evident as doses
are escalated because these tissues are much less readily
protected than hematopoietic stem cells.
GENE MARKING AND PEDIATRIC MALIGNANCIES
The principle of gene marking is the transfer of a
unique DNA sequence (eg, a nonhuman gene) into a host
cell (eg, T cell, hematopoietic stem cell, etc) allowing the
gene or the gene product to be easily detected, thereby
serving as a marker for these labeled cells [42].
In all these studies, gene marking is not intended for
direct therapeutic beneﬁt, but rather to obtain informa-
tion regarding the biology and function of adoptively
transferred cells.
Genemarkingforautologousstemcell
transplantation
By marking stem cells prior to stem cell infusion,
it has been possible to determine if contaminating ma-
lignant cells in the stem cell harvest contribute to re-
lapse following autologous stem cell transplant [43]. The
hematopoietic stem cell (HSC) product is marked at the
time of harvest with murine retroviral vectors encoding
the neomycin resistance gene. Then, at relapse, it is pos-
sible to detect whether the marker gene is present in the
malignant cells. Since 1991, studies have been initiated
using this approach in a variety of malignancies treated
by autologous HSC transplantation [43, 44, 45, 46] in-
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leukemia (CML), acute lymphoblastic leukemia (ALL),
neuroblastoma, and lymphoma.
In pediatric patients, receiving autologous BMT as
part of therapy for AML, four of twelve patients who re-
ceived marked marrow relapsed. In three of the four pa-
tients, detection of both the transferred marker and the
tumor-speciﬁc marker in the same cells at the time of re-
lapseprovidedunequivocalevidencethattheresidualma-
lignant cells in the marrow were a source of leukemic re-
currence [42]. These marking studies also provided in-
formation on the transfer of marker genes to normal
hematopoietic cells and showed that marrow autografts
contribute to long-term hematopoietic reconstitution af-
ter transplant [47]. Long-term transfer for more than 10
years has been seen in the mature progeny of marrow pre-
cursor cells, including peripheral blood T and B cells and
neutrophils [48].
GenemarkingofTcells
Several studies have also shown the feasibility of gene
marking cytotoxic T lymphocytes (CTL) to track their ex-
pansion, persistence, and homing potential to the sites of
disease [49, 50, 51]. For example, gene marking of Ep-
stein Barr virus (EBV)-speciﬁc CTL for the prophylaxis
and treatment of lymphoproliferative disorder posthe-
matopoietic stem cell transplant has demonstrated per-
sistence of gene marked CTL to 78 months post-infusion
[52]. In addition, as described below, gene-marked EBV-
CTL given as treatment for relapsed Hodgkin disease have
been shown to traﬃct ot u m o rs i t e s[ 51].
GENE MODIFICATION OF THE IMMUNE RESPONSE
Renderingthetumormoreimmunogenic
One of the most striking observations of the past 10
years has been the demonstration that human tumors
widely express tumor associated or tumor speciﬁc anti-
gens. Moreover, even if these are internal antigens, they
may be processed and presented by the tumor cell and
become targets for the immune response. These antigens
may be particularly prevalent on pediatric malignancies
whichfrequentlyexpressoncofetalordevelopmentalanti-
gens not present in the mature child or which may express
antigens directly relating to the genetic lesions that have
caused the tumor [3, 53].
One of the most commonly used approaches to can-
cer gene therapy is the attempt to enhance the immuno-
genicity of these weak tumor antigens and to amplify the
scanty T cell precursors capable of recognizing them. An
immune response to any antigen has a number of diﬀer-
ent phases. These include antigen processing and presen-
tation, chemoattraction of T cells to the site of the pre-
sented antigen, the costimulation of any T cell which en-
gages the antigen with its speciﬁc receptor and the am-
pliﬁcation of the immune response so generated. Each of
these stages is the primary responsibility of one or more
of a range of secreted chemokines and cytokines or of
cell-bound receptor-ligand systems. It has become appar-
ent that the forced expression of one or more of these
agents within a tumor cell is capable of greatly enhanc-
ing the immune response to the weak tumor antigens that
cell may express. The immune response so generated may
then be eﬀective elsewhere in the body against nontrans-
duced cells. This immunologic bystander eﬀect is an im-
portant consideration, since the ineﬃciency of vectors,
currently available, makes the probability of transducing
all tumor cells in a patient exceedingly remote. Hence,
by transducing even a small proportion of cells, it may
be possible to use the eﬃcient targeting mechanisms of
the immune system to ensure that the response aﬀects the
bulk of tumor cells, including those that were not geneti-
cally modiﬁed.
Geneticmodiﬁcationoftumorcells
An u m b e ro fd i ﬀerent agents have been successfully
utilized in animals, including chemokines such as lym-
photactin [54], agents which enhance antigen presenta-
tion such as GM-CSF [55, 56, 57], and cytokines that
enhance CD4 cell activity (eg, TNF and Interleukin 7)
[58, 59], increase expression of class I MHC antigens (eg,
gamma Interferon) [60], or amplify T cell responses (eg,
Interleukin 2) [61]. Additionally, eﬀorts have been made
to express costimulator molecules on tumor cells, includ-
ing CD40 Ligand [62, 63, 64, 65, 66] and B7.1 [67], or in-
tercellular adhesion molecules such as ICAM 1 and ICAM
3[ 68].
Sourceofcells
The cells used for gene-modiﬁed tumor immunother-
apy may be derived either from the patient themselves
or from an allogeneic cell line grown in culture. Each of
these approaches has reciprocal advantages and disadvan-
tages. For example, an autologous cell line, unlike an al-
logeneic cell line, will almost certainly express the tumor
speciﬁc antigens that are present elsewhere in the patient.
The heterogeneity of human tumors means that this may
not be so for an allogeneic tumor cell line. An autolo-
gouscelllinewillalsoexpressthesetumorassociatedanti-
gens in the context of the patient’s own MHC molecules,
and so will be recognized by the host immune system.
An allogeneic cell line will likely only do this if the anti-
gens on that cell line are taken up by host antigen pre-
senting cells and subsequently presented to the host im-
mune system (cross priming). The clear advantages of al-
logeneic tumors are that they are much more readily ob-
tained in quantity than autologous tumors, which may be
diﬃcult to harvest in adequate numbers to generate a vac-
cine. Allogeneic cells are also much easier to standardize,
sincetheleveloftransgeneexpressionwillbeconstantand
will not vary from patient to patient. This makes the de-
sign and interpretation of clinical trials much simpler. Fi-
nally, from a practical point of view, should a tumor vac-
cine be promising in early phase clinical study, the devel-
opment of an allogeneic vaccine would be substantially18 Ettore Biagi et al 2003:1 (2003)
facilitated, since the material could be manufactured,
tested, and stored in bulk rather than generated as an in-
dividualized therapy for each patient in a large study. For
themoment,itseemsreasonabletostudybothautologous
and allogeneic tumor cells and to decide which approach
is optimal when more information is available.
Pediatricclinicalstudieswithgenemodiﬁed
tumorcells
Neuroblastoma cells were transduced with adenovi-
ral vectors so that they expressed the Interleukin 2 gene.
Both autologous and allogeneic studies were instituted.
In the autologous trial, patients received up to 8 injec-
tions of their own tumor cells subcutaneously. More than
half the patients produced speciﬁc antibody and a spe-
ciﬁc cytotoxic T cell response directed against the autol-
ogous neuroblasts. Of 10 patients, 5 had clinical tumor
responses including one complete and one very good par-
tial response [69]. In the allogeneic study, however, the
immunizing cell line induced no evident speciﬁc immu-
nity and only one patient showed a partial response [70].
Of note, in both studies a signiﬁcant number of children
showed good tumor responses on subsequent treatment
with low dose oral etoposide. This interaction between
genetic immunotherapy and low dose chemotherapy has
subsequently been observed in a number of adult tumor
vaccine studies, and likely represents a genuine interactiv-
ity between these treatment modalities that may usefully
be exploited for therapeutic beneﬁt in the future.
A subsequent clinical study in neuroblastoma was
based upon animal data showing that the combination
of lymphotactin (Lptn), a T cell chemokine, and Inter-
leukin 2 (IL-2), the T cell growth factor, accelerated and
augmented the immune response to a neuroblastoma cell
line [54]. Accordingly, patients received either an autol-
ogous vaccine or an allogeneic one expressing both IL-2
and Lptn [71]. In the allogeneic group, it was possible for
the ﬁrst time to observe speciﬁc antitumor immune re-
sponses to the immunizing cell line, and two patients en-
tered complete remission, which was durable in one. In
theautologousstudy,theresultsdidnotappeartobemea-
surably superior to Interleukin 2 alone. Hence, in the al-
logeneic setting at least, there is preliminary evidence that
thecombinationoftwoagentsactingatdiﬀerentphasesof
the immune response may be superior to a single agent. If
these results are conﬁrmed they may increase the feasibil-
ity of utilizing allogeneic vaccines with the considerable
simpliﬁcation in protocol development that would result.
In hematologic malignancy, a Phase I study of autol-
ogous acute myeloblastic leukemia cells engineered to se-
crete GM-CSF has recently commenced and this study is
now being extended to pediatric AML [57].
It has also proved feasible to express costimulator
molecules such as CD40, CD40 Ligand, or B7.1 on pri-
mary tumor cells surfaces. We are currently using a com-
bination of CD40 Ligand and IL-2 gene transfer into pe-
diatric acute lymphoblastic leukemia cells in an eﬀort to
generate an antitumor immune response in patients with
high-risk disease who have entered remission. To date,
t h i ss t u d yh a sp r o v e dt ob es a f ea n dh a sg e n e r a t e da n -
tileukemia immune responses. Because these patients are
treated in remission, we do not yet know whether there
has been any antileukemia activity.
In conclusion, therefore, genetic modiﬁcation of tu-
mor cells appears safe and is capable of generating spe-
ciﬁc humoral and cellular antitumor cytotoxic responses.
There have been at least some tumor regressions and the
approach is now being evaluated in a wider range of tu-
mors and in a larger number of patients.
PEDIATRIC CANCER THERAPY WITH GENE
MODIFIED T CELLS
ProphylaxisandtreatmentofEpsteinBarrvirus
(EBV)-associatedposttransplantlymphoproliferative
disorder(EBV-PTLD)
Several studies have suggested the feasibility and ap-
parent clinical eﬃcacy of adoptive transfer of cytotoxic T-
cells (CTL) directed at viral or tumor antigens [50, 72, 73,
74]. By using gene-marked cells in these studies, it has not
only been possible to determine the survival and homing
of the infused T-cells, but also determine if they mediate
adverse eﬀects such as GvHD [75, 76].
For example, Epstein Barr virus (EBV)-associated
posttransplant lymphoproliferative disorder (PTLD) is a
complication due to proliferation of EBV-infected B cells
and occurs in 5–30% of patients receiving T-depleted
marrows from mismatched family or unrelated donors.
Several groups have investigated the feasibility of gener-
ating donor-derived EBV-speciﬁc CTL to treat this disor-
der [77, 78, 79, 80]. Our group generated EBV-speciﬁc T
cell lines from donor lymphocytes and used them as pro-
phylaxis and treatment for EBV-PTLD in patients post
HSCT [77]. Over a 7-year period, 56 pediatric patients
who received a T cell-depleted HSCT were given EBV-
CTL prophylactically. The ﬁrst 26 patients enrolled on to
the study received CTL marked with the neomycin re-
sistance gene. None of the 56 patients who received the
EBV-CTL developed PTLD compared with an incidence
of 11.5% in a comparable group who did not receive CTL
[81]. Using conventional PCR and real-time PCR, the
marker gene was identiﬁed in the peripheral blood for at
least 78 months post CTL [82]. Three patients who de-
clined or were ineligible for our prophylaxis study were
treated for established EBV lymphoma. The EBV-speciﬁc
CTL therapy induced sustained remission in 2 patients,
but the third patient treatment failed and was found
to have an antigen-loss mutant in her EBV lymphoma
cells [83].
These studies are now being extended to patients
receiving solid organ transplants. Pediatric populations
are particularly susceptible to PTLD after solid organ
transplant, because children are more frequently EBV-
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AdoptiveimmunotherapyforEBV-positive
Hodgkindisease
EBV-positive lymphoma cells in posttransplant lym-
phoproliferative disease, express a wide range of EBV
encoded antigens and are readily susceptible to im-
munotherapy. What of the malignant cells of Hodgkin
disease and Nasopharyngeal cancer, which express a more
restricted pattern of antigens? More than 80% of chil-
dren with EBV-associated Hodgkin disease can be cured,
but treatment for those who relapse is limited. More-
over, long-term follow-up studies of Hodgkin disease sur-
vivors show greatly increased risks of second malignancy
[85]. Nonfatal sequelae of therapy, such as altered somatic
growth, infertility, and restrictive lung disease can also se-
riously aﬀect the quality of the life of the survivors [86].
It is therefore desirable to develop novel therapies that
could improve disease-free survival in relapsed/refractory
patients and reduce long-term complications.
We have treated 13 patients with EBV+ Hodgkin dis-
ease using EBV-speciﬁc CTL. Five patients with minimal
residual disease postautologous bone marrow transplant
remain well for 2–21 months post CTL infusion [87], and
mixed tumor responses in 6 patients. Of 8 patients treated
withactivedisease,injectionofEBV-speciﬁcgene-marked
CTL showed gene-marked CTL within tumor [51] and in
peripheral blood for up to 9 months following infusion
[87].
Futuretrendsinthedevelopment
ofgene-modiﬁedCTL
Although these results have been promising and there
have been tumor responses, these have been partial, or
often transient, and no patient with aggressive relapsed
Hodgkindiseasehasbeencured.Thismaybeduetoalack
ofspeciﬁcityoftheEBV-speciﬁcCTLfortheimmunosub-
dominant LMP1 and LMP2 antigens that are all present
on the Hodgkin tumor. In addition, the tumor secretes
immunosuppressive cytokines and chemokines which af-
fect CTL function and antigen presenting cell activity
[88]. Gene transfer can be used to overcome both types of
problems. By using dendritic cells transduced with ade-
noviral vectors encoding LMP2, it has proved possible
to generate CTL that have high cytolytic activity in vitro
to LMP2-positive targets when compared to conventional
EBV-CTL [89, 90].
Although such speciﬁc cells may be more eﬀective,
there is a concern that the CTL will remain vulnera-
ble to the immunosuppressive cytokines secreted by the
HodgkinReed-Sternbergcell.Thecytokine,whichhasthe
most devastating eﬀects on CTL proliferation and func-
tion, is transforming growth factor-beta (TGFβ)[ 91, 92].
This cytokine is secreted by a wide variety of child-
hood tumors, and allows the tumor to escape the im-
mune response [93]. To overcome this capacity to in-
hibit the EBV-CTL, we transduced CTL from patients
with relapsed EBV-positive Hodgkin disease with a retro-
virusvectorexpressingadominant-negativeTGFβ type-II
receptor (DNR). This prevents formation of the func-
tional trimeric receptor. Cytotoxicity, proliferation, and
cytokine release assays showed that exogenous TGFβ
had minimal inhibitory eﬀects on DNR-transduced CTLs
[94]. This combination of tumor-speciﬁc and tumor-
resistant CTL may prove highly eﬀective for therapy.
AdoptiveimmunotherapyforEBV-positive
Nasopharyngealcarcinoma
Despite the good overall survival rates following con-
ventional therapy for this disease in children, follow-up
reports have shown substantial longer-term treatment-
related morbidity and mortality [95, 96], including
growth hormone deﬁciency, hypothyroidism, pulmonary
ﬁbrosis, and secondary malignancies [96, 97]. Although
EBV-CTL have been used in this disease, [98] with lim-
ited success, we are using the same approaches described
for Hodgkin disease to treat these tumors as well.
ChimericTcellsfortumortherapy
Primary T cells genetically modiﬁed to express chime-
ric receptors derived from antibodies and speciﬁc for tu-
mor or viral antigens have considerable therapeutic po-
tential. Chimeric T cell receptors allow the recognition
speciﬁcity of T lymphocytes to extend beyond classical
T cell epitopes by transducing cells with genes that en-
code the variable domain of a tumor-speciﬁc monoclonal
antibody (MAb) (ScFv) joined to a cytoplasmic signaling
domain. This strategy can therefore be applied to every
malignancy that expresses a tumor-associated antigen for
which an MAb exists [99, 100]. Unlike conventional T cell
receptors, these chimeric receptors will be active even if
the tumor cells are class-1-MHC negative.
Neuroblastoma is the commonest extracranial solid
tumor of children, and is often resistant to conventional
treatments. A high proportion of tumors express tumor-
associated antigens such as GD2, L1-CAM, and N-CAM.
CD8+ve CTL clones genetically modiﬁed to express the
CE7R chimeric immunoreceptor which consists of an ex-
tracellular L1-CAM-speciﬁc single-chain antibody, trans-
membrane CD4, and T cell CD3-complex zeta chain, is
currently being investigated in a clinical trial [101]. How-
ever, chimeric receptor signaling produces only limited
activation of the T cells, and we are currently exploring
an alternative approach to increase the in vivo function-
ality of the cells [102, 103]. We have transduced EBV-
speciﬁc (not primary) T cells with GD2-speciﬁc chimeric
receptor genes. In in vitro, we have shown that these cells
can be expanded and maintained long term in the pres-
ence of EBV-infected B cells. While they recognize EBV-
infected targets through their conventional T cell receptor
and thereby become activated, they are also able to recog-
nize and lyse tumor targets through their chimeric recep-
tors. Several cycles of virus target → tumor target → virus
target can be demonstrated ex vivo, implying that EBV-
speciﬁc T cells expressing chimeric antitumor receptors
may represent a new source of eﬀector cells that would20 Ettore Biagi et al 2003:1 (2003)
persist and function long term after their transfer to can-
cer patients [104].
CONCLUSION
W eh a v ef a rt og ob e f o r eg e n et h e r a p yo fp e d i a t r i c
malignancy can truly be said to have made a major im-
pact on these diseases. Nonetheless, over the past decade,
these new techniques have produced unequivocal tumor
responses even in advanced disease. As we continue to
make incremental advances in the application of these ap-
proaches, we can expect to see gene therapy increasingly
supplement and perhaps even eventually supplant con-
ventional cancer therapeutics.
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